Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRICK-MCC: Combination Immunotherapy in Refractory Merkel Cell Carcinoma
NCT06056895Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Nov 2023
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab, tuparstobart and verzistobart in Merkel cell carcinoma (MCC), sponsored by University of Washington. Primary endpoint: Objective Response Rate up to 5 years. Started Nov 2023; status: active, not recruiting.
02
Drugs
retifanlimabtuparstobartverzistobart
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT06056895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056895.